Despite encouraging clinical evidence, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is facing significant opposition from PBMs. Such organizations are often erecting obstacles to access, such as significant cost restrictions and approval processes tha